IL7 and myeloid sarcoma: These findings suggest that the IL‐7 signaling pathway may be a key regulatory factor driving the differentiation of MAIT cells in patients with MS toward a Th17‐like proinflammatory phenotype, thereby participating in the neuroinflammatory pathological process of MS [180].